1	Postprint of: Waraksa E., Owczarek K., Kubica P., Kłodzińska E., Ozimek M., Wrzesień R.,
2	Bobrowska-Korczak B., Namieśnik J., Determination of bromhexine and its metabolites in
3	equine serum samples by liquid chromatography – Tandem mass spectrometry: Applicability
4	to the elimination study after single oral dose, Journal of Chromatography B, Vol. 1151 (2020),
5	122197, DOI: <u>10.1016/j.jchromb.2020.122197</u>
6	© 2020. This manuscript version is made available under the CC-BY-NC-ND 4.0
7	license http://creativecommons.org/licenses/by-nc-nd/4.0/
8	Determination of bromhexine and its metabolites in equine serum samples by liquid
9	chromatography – tandem mass spectrometry: Applicability to the elimination study
10	after single oral dose
11	Emilia Waraksa ^{a,b*} , Katarzyna Owczarek ^a , Paweł Kubica ^a , Ewa Kłodzińska ^b , Mariusz Ozimek ^b ,
12	Robert Wrzesień ^c , Barbara Bobrowska-Korczak ^d , Jacek Namieśnik ^{‡ a}
13	Affiliations
14	^a Gdańsk University of Technology, Faculty of Chemistry, Department of Analytical
15	Chemistry, G. Narutowicza 11/12 Street, 80-233 Gdańsk, Poland
16	^b Institute of Sport - National Research Institute, Department of Analytical Chemistry and
17	Instrumental Analysis, Trylogii 2/16 Street, 01-982 Warsaw, Poland
18	^c Medical University of Warsaw, Central Laboratory of Experimental Animal, Banacha 1 B
19	Street, 02-097 Warsaw, Poland
20	^d Medical University of Warsaw, Department of Bromatology, Banacha 1 B Street, 02-097
21	Warsaw, Poland
22	* Correspondence to: Emilia Waraksa, e-mail: emilia.waraksa@insp.waw.pl

Keywords: bromhexine, metabolites of bromhexine, liquid chromatography – tandem mass
 spectrometry, elimination study, doping, equestrian sports

25 Highlights

• Time curses of BH and its metabolites concentrations determined for the first time in equine serum.

28

29

• Fully validated LC-MS/MS method for determination of BH and its metabolites in equine serum samples.

• Simple sample preparation utilizing acetonitrile protein precipitation.

31 Abstract

32 Bromhexine (BH), expectorant used in the treatment of respiratory disorders associated with viscid or excessive mucus, is not permitted for use in the competing horse by many 33 34 authorities in horseracing and Olympic disciplines. Metabolic studies are of the great 35 importance in anti-doping field because they allow for updating the selection of the most 36 appropriate markers for prohibited substances, such as metabolites present at higher 37 concentration levels and/or lasted for a longer period of time in biological samples than a parent 38 drug. This study describes LC-MS/MS-based method for simultaneous determination of BH 39 and its metabolites, including 4-(2-amino-3,5-dibromobenzylamino)cyclohexanol (4-HDMB), 40 3-(2-amino-3,5-dibromobenzylamino)cyclohexanol (3-HDMB), in equine serum samples. The 41 2-(2-amino-3,5-dibromobenzylamino)cyclohexanol (2-HDMB) was monitored as well. The assay was validated in terms of linearity (R²>0.9951), intra- and inter-assay accuracy (91.6 – 42 109.1%) and precision (CV<9.6%) as well as recovery (94.8 – 105.65%). The LODs were 43 44 0.0052, 0.0053, 0.0056 and 0.0043 ng/mL for BH, 2-HDMB, 3-HDMB and 4-HDMB, 45 respectively. The developed method was applied to determine the time curses of BH and its 46 metabolites concentrations in equine serum collected for 95.25 h following a single oral

administration of BH to two healthy mares (in dose of 0.8 mg/kg). The parent drug was found
at higher concentration levels than 3-HDMB (major metabolite) and 4-HDMB (minor
metabolite), however, both BH metabolites lasted for a longer period of time in equine serum
than the parent drug. Thus, both metabolites of BH can be considered as BH abuse markers.



51

52 **1. Introduction**

53 The issue of affecting efficiency of horses using performance-enhancing and 54 performance-impairing substances or methods is of the most importance in equestrian sports. 55 Although, there is no single organization regulating anti-doping framework, the individual authorities provide rules and regulations to ensure the integrity of the sport as well as the welfare 56 57 of horses [1]. Among them, the International Federation of Horseracing Authorities (IFHA) 58 implemented a guide for horseracing activities - the International Agreement on Breeding, 59 Racing and Wagering (IABRW) [2], and the authority for Olympic disciplines, Fédération 60 Equestre Internationale (FEI), published the Equine Prohibited Substances List (EPSL) [3] that 61 categorize prohibited substances.

Bromhexine (BH), known as 2-amino-3,5-dibromo-N-cyclohexyl-Nmethylbenzylamine, is an expectorant used in the treatment of respiratory disorders associated

64 with viscid or excessive mucus. BH acts on respiratory system and it is listed in the EPSL as a 65 controlled substance, so its usage is prohibited by both IFHA and FEI regulations. In mammals, BH was found to be extensively converted to several metabolites, including 4-(2-amino-3,5-66 67 dibromobenzylamino)cyclohexanol (4-HDMB. ambroxol) and 3-(2-amino-3,5-68 dibromobenzylamino)cyclohexanol (3-HDMB) [4-9]. In general, the presence of doping 69 substance metabolite(s) in biological samples provide(s) additional confirmation of drug 70 identification and information on its misuse, even when the primary compound could not be 71 detected. This is especially important for highly metabolized doping agents, which are present 72 in biological samples at higher concentrations and/or lasted for a longer period of time than a 73 parent drug. Moreover, doping substances can be converted to active metabolites, such as BH 74 into 4-HDMB, which also causes an action on the respiratory tract and it is listed in the EPLS 75 as a controlled compound. The most recent reports on pharmacokinetics [8], excretion and 76 metabolic patterns of BH [9] in horses is dated more than 20 years ago. Several metabolites 77 have been identified in equine urine samples following BH and its active metabolite 4-HDMB 78 administration [9]. Nevertheless, metabolites of BH in equine plasma, serum neither whole 79 blood following drug administration have not been investigated yet.

80

81

82

83

84

85

86

87

88

Among different methods for determination of BH and/or its metabolites in biological samples [6-7, 10-13] and pharmaceutical formulations [14-22] one can distinguish UV-Vis spectrophotometry [14-16], thin layer chromatography (TLC) [17], capillary electrophoresis (CE) [10, 18], high performance liquid chromatography – ultraviolet detection (HPLC-UV) [12-13, 19-21], liquid chromatography – mass spectrometry (LC-MS) [22] and liquid chromatography – tandem mass spectrometry (LC-MS/MS) [6-7]. Although methods using HPLC-UV are still widely applied in quantification of BH and 4-HDMB in pharmaceutical formulations, LC-MS and LC-MS/MS-based assays are probably the most popular choice for their determination in biological samples. Methods using LC-MS and LC-MS/MS provide fast

analysis, often omitting time-consuming and complicated sample preparation, including liquidliquid extraction (LLE) [12-13] and solid-phase extraction (SPE) [11], while guaranteeing
significantly better sensitivity compared to HPLC-UV-based procedures. The recent literature
reports [6-7] indicated LC-MS/MS-procedures as a powerful tool for determination of BH and
its metabolites in biological samples of mammals.

94 The purpose of this study was to develop and validate a novel, rapid and sensitive 95 LC-MS/MS method for simultaneous determination of BH and its metabolites in equine serum 96 samples. The previously described study was focused on a method based on SPE and 97 RRLC-MS/MS for determination of these compounds in human plasma samples [7]. To the 98 best of our knowledge, it is the first study describing elimination process of BH in horses. The 99 sample preparation procedure was limited to protein precipitation (PPT) using acetonitrile and 100 centrifugation of samples. The method proposed in this study allowed for simultaneous 101 determination of BH and its metabolites in a 10-min-long analytical run. The proposed assay 102 seems to be suitable for routine doping control analysis due to effortlessness of the sample 103 preparation procedure, obtained values of LOQs at pg/mL (13 – 17 pg/mL; in comparison – the 104 previously described method [7] achieved LOQs within 50 -150 pg/mL) and high recovery 105 (94.8 – 105.65%; in comparison – in the previously described method [7] recovery was in the 106 range of 57.0 - 70.9%). The developed and fully validated method has been successfully 107 applied to analysis of real samples collected for 95.25h after a single oral administration of BH 108 to two healthy mares. As a result, concentration-time curves of 3-HDMB and 4-HDMB in 109 equine serum were determined for the first time along with BH. The study indicated both BH 110 metabolites as appropriate BH abuse markers since they last for a longer period of time in 111 equine serum than the parent drug

112

113 **2.** Materials and methods

114 **2.1 Standards and reagents**

Racemic-4-(2-amino-3,5-dibromobenzylamino)cyclohexanol (4-HDMB), *racemic*-3(2-amino-3,5-dibromobenzylamino)cyclohexanol (3-HDMB), *racemic*-2-(2-amino-3,5dibromobenzylamino)cyclohexanol (2-HDMB) were purchased from ChiroBlock GmbH
(Bitterfeld Wolfen, Germany). Diphenhydramine (used as ISTD) was obtained from SigmaAldrich Chemical Co. (St. Louis, MO, USA). All of the standards have a minimum purity of
95%.

Water (LC-MS grade), methanol (MeOH; LC-MS grade), and acetonitrile (ACN;
LC-MS grade) were obtained from Honeywell Burdick & Jackson Company (NJ, USA).
Hydrochloric acid (35–38%; pure p.a.) was purchased from POCH (Gliwice, Poland).

124

2.2 LC-MS/MS conditions

125 The analysis of equine serum samples were performed on a LC-MS/MS system (LCMS-126 8060, Shimadzu, Japan) equipped with an electrospray ionisation source (ESI) working in a 127 positive mode of multiple reaction monitoring (MRM). The parameters of ion source were as 128 follows: nebulizing gas flow of 3 L/min; heating gas flow of 10 L/min; interface temperature 129 of 300°C; desolvation line temperature of 250°C; heat block temperature of 400°C; and drying gas flow of 10 L/min. Conditions of ion transitions were optimized for all analytes using 130 131 LabSolutions v.5.85 Software. Detailed information on MS/MS transitions, specific parameters and structures of compounds are given in Table 1. 132

Chromatographic separation was carried out using UPLC Nexera X2 system (Shimadzu,
Japan) consisting of degasser DGU-20A5R, controller CBM-20A, binary pump LC-30AD,

135 autosampler SIL-30AC and column oven CTO-20AC. Chromatographic separation was 136 achieved using Kinetex core-shell C_{18} column (15cm \times 2.1mm, 2.6µm) with C_{18} guard column 137 (0.5cm x 2.1mm, 2.6µm) from Phenomenex (Torrance, USA). The column temperature was 138 kept at 30°C. The flow rate of the mobile phase was set at 1 mL/min; and the injection volume 139 was set at 5 μ L. For the mobile phase, following solvents were used: A) water + 0.1% formic 140 acid, and B) acetonitrile + 0.1% formic acid. The analytes were eluted with following gradient 141 program: 0 – 0.50 min 10% B, 0.50 – 5.50 min 10 – 35% B, 5.50 – 7.00 min 35 – 95% B. The 142 column was stabilized after each analysis for 3 min. The total time of the chromatographic run 143 was 10 min.

144

151

2.3 Drug administration, samples collection and storage

Two healthy mares received a single oral dose of bromhexine (400 mg; 0.8 mg/kg). The blood samples were collected before and after 1,3, 5, 8, 11.5, 15.5, 19.5, 23.5, 29.25, 35, 41, 48, 53, 59.5, 72, 83 and 95.25 h of drug administration. All samples were stored at –20°C before the analysis. The study was approved by the Local Ethical Committee for Animal Experimentation at the Faculty of Biology, University of Warsaw, Poland (Decision no. 565/2018).

2.4 Preparation of stock, working and quality control solutions

A stock solutions of each analyte were prepared at concentration of 1 mg/mL by dissolving of accurately weighted reference substances in water. Working solutions were prepared as a mixture of analytes at concentrations of 100, 10, 1, 0.1, 0.01 μ g/mL for each compound. ISTD stock solution was prepared at concentration of 1 mg/mL by dissolving accurately weighted reference substance in water. ISTD working solutions were prepared at concentrations of 1 and 0.02 μ g/mL by diluting the ISTD stock solution with water.

Because the method covers a wide concentration range (0.025 - 500 ng/mL), two separate calibration curves were prepared (0.025 - 1 and 1 - 500 ng/mL). For this purpose, calibration solutions were prepared in triplicate at concentrations of 0.025, 0.05, 0.15, 0.25, 0.5, 1, 5, 25, 50, 100, 200 and 500 ng/mL for all analytes by fortifying 200 µL of blank equine serum with appropriate volumes of the working solutions. ISTD concentration was kept at 1 ng/mL in calibration samples in the range of 0.025 - 1 ng/mL, and at 50 ng/mL in calibration solutions within 1 - 500 ng/mL.

Quality control (QC) samples at six concentration levels (0.05, 0.25, 1, 5, 50 and ng/mL) were prepared. ISTD concentration was at 1 ng/mL for QC samples at concentrations of 0.05, 0.25 and 1 ng/mL, and at 50 ng/mL for QC samples at concentrations of 5, 50 and 200 ng/mL.

169 Both calibration solutions and QC samples were treated according to the sample 170 preparation procedure (matrix-matched calibration curve) and analyzed by LC-MS/MS system.

171

2.5 Sample preparation

172 A 200 μ L of equine serum, 10 μ L of the ISTD working solution at 0.02 μ g/mL, 200 μ L 173 of acetonitrile were added to a Eppendorf vial and refrigerated (3°C) for 1 h. After 174 centrifugation for 5 min at 13000 rpm, supernatant was analyzed by LC-MS/MS system. When 175 analyte(s) was (were) determined at concentration(s) above 1 ng/mL, a 200 μ L of equine serum 176 was spiked with 10 μ L of the ISTD working solution at 1 μ g/mL and reanalyzed as described 177 above.

2.6 Method validation

The method was validated in terms of matrix effects (ME), linearity, limit of detection(LOD) and quantification (LOQ) values, accuracy, precision, recovery (RE) and carry over

[‡] This article is dedicated to the memory of Prof. Jacek Namieśnik (1949 – 2019).

178

effects. All validation experiments were designed according to the principles for bioanalyticalmethod validation [23-26].

183

3. Results and discussion

3.1 Optimization of sample preparation procedure

185 In this work, sample pretreatment strategy was focused on proving high selectivity and 186 sensitivity using a fast and simple procedure with a small sample volume (200 μ L) and low 187 consumption of organic solvents (200 µL of acetonitrile). A one-step sample preparation 188 method using protein precipitation (PPT) through the use of acetonitrile was proven to get 189 sufficient clean samples usable for LC-MS/MS analysis. Proteins can be irreversibly adsorbed 190 onto the chromatographic support, which causes the deterioration of separation efficiency, 191 peaks symmetry and a rapid column clogging. Therefore, protein-rich matrices, such as serum 192 samples containing large amounts of albumin and immunoglobulins, require protein removal 193 before analysis. For this purpose, PPT was chosen due to the simplicity of the technique. Two 194 organic precipitation agents, ACN and MeOH, were tested. Data on the recovery rates of all the 195 analytes when ACN and MeOH was used are presented in Supplementary Table 1. Finally, 196 ACN was chosen on the basis of significantly higher recoveries for all analytes compared to 197 using MeOH.

198

199

200

201

202

203

204

3.2 Optimization of LC-MS/MS parameters

The LC-MS/MS conditions were optimized to ensure selectivity and sensitivity of the method. Preliminary studies, involving the investigation of two chromatographic columns for the analytes separation were performed. Structural (geometric isomers) and physicochemical similarities of the target compounds make them difficult to separate, so high resolution is desirable. Because of that reason, columns packed with core-shell particles were tested, i.e. Kinetex core-shell C_{18} column (15 cm \times 2.1 mm, 2.6 µm) with guard column

205 (0.5 cm x 2.1 mm, 2.6 μ m) from Phenomenex (Torrance, USA) and Ascentis Express® 206 C₁₈ column (15 cm × 2.1 mm, 2.7 μ m) with guard column (0.5 cm × 2.1 mm, 2.7 μ m). The use 207 of the Kinetex column allowed to obtain higher instrumental responses (mainly for BH), more 208 symmetrical and narrower peaks, increased separation efficiency and significantly shorter 209 analysis time compared to using Ascentis Express® column. Therefore, Kinetex column was 210 chosen for future studies. Appropriate chromatograms obtained in the preliminary studies are 211 presented in Supplementary Fig. 1.

Formic acid and ammonium formate were tested as the mobile phase modifiers. Compared to the use of ammonium formate, formic acid additive provided better resolution and higher response for all analytes. Better peak shapes, including improved symmetry factor and minimized tailing, were obtained when formic acid was used compared to annonium formate. The gradient profile, column temperature, flow rate and injection volume were adjusted as well.

217 MRM transitions were chosen for each analyte on the basis of signal and characteristic218 fragment ions.

219 **3.3 Method validation**

The developed procedure meets specified performance requirements and it is acceptable for its intended use. The summary of method validation results was shown in Table 2 and Table 3.

Two linear calibration curves covering the low concentration range within 0.025 – 1 ng/mL and the high concentration range of 1 – 500 ng/mL were used for BH, 2-HDMB, 3-HDMB and 4-HDMB. Linear calibration equations were obtained for calibration curves constructed by plotting analyte-to-ISTD peak area ratios versus corresponding concentrations. Calibration curves covered a broad concentration range, thus weighting factor 1/x was applied to each one for increasing the accuracy at the lowest concentration levels.

Obtained coefficients of determination for the calibration curves were greater than 0.9951 forall target analytes.

LODs and LOQs were established on the basis of six-point matrix-matched calibration curves in the concentration range of 0.025 - 1 ng/mL for all analytes, using following equations: LOD = $(3.3S_b)/a$ and LOQ = $(10S_b)/a$ where: Sb – standard deviation of intercept of the calibration curve, a – slope of the calibration curve. The proposed method was found to be sensitive (LOD was 0.0052 ng/mL for the parent compound and within 0.0043 – 0.0056 ng/mL for metabolites of BH).

237 Matrix effects (ME) were calculated by comparing the slopes of calibration curves, 238 according to the following formula: ME= $(a_m/a_r - 1) \times 100\%$, where a_m and a_r are the slopes of 239 the curves prepared in blank equine serum and solvent, respectively. Negative values of ME 240 indicate signal suppression, while positive values signify enhancement of the signal. Matrix 241 effects at values of -20% 242 -50<ME<-20 as medium, and ME>±50 as large. The obtained results indicated signal 243 suppression for all analytes, medium for BH (in both the low and the high concentration ranges), 244 soft (in the high concentration range) and medium (in the low concentration range) for 245 2-HDMB, 3-HDMB and 4-HDMB. For medium and/or large ME, the application of methods 246 for reducing the influence of the matrix are required. Therefore, the matrix-match calibration 247 was used for all investigated compounds.

The intra- and inter-assay accuracy and precision were assessed. For this purpose, QC samples (n=6) were analyzed by LC-MS/MS system on the same day and over three consecutive days, respectively. Intra- and inter-day accuracy was calculated according to the following formula: A=($C_m - C_n$)/ $C_n \times 100\%$, where C_m is the mean measured concentration and C_n is the nominal concentration. Intra- and inter-assay precision was assessed as the coefficients

of variation (CVs). Both intra and inter-day accuracy was in the range of 91.6 – 109.1%.
CV was found to be less than 9.6%.

- The recovery was assessed by comparing the analyte-to-ISTD peak area ratios obtained for pre- and post-extracted fortified blank equine serum samples (n=6) at QC samples levels. The results indicated that recovery was within 94.8 – 105.65%.
- Carry-over effect was verified by injecting blank samples after the upper limit of
 quantification in all analytical runs. Carry-over effect was found to be insignificant on the basis
 of analyte-to-ISTD peak area ratios (below 0.1%) for blank samples.

Stability of the analytes were investigated at QC samples levels by analyzing samples stored at room temperature (RT) for 24 h, samples stored at 4°C for 24 h, and samples three times freezed (at -20°C) and then defrosted. The accuracy was within 94.8 – 109.8% for samples stored at RT for 24 h, 91.6 – 109.7% for samples stored at 4°C for 24 h, and 95.4 – 109.7% for samples after three freeze/thaw cycles. The CV was found to be less than 9.9% for all examined samples.

267

3.4 Analysis of real samples

268 The developed and validated method was applied to the quantification of BH and its 269 metabolites in real samples. For this purpose, equine serum samples (n=3) were treated 270 according to the sample preparation procedure (described above) and analyzed by LC-MS/MS 271 system. BH and its two metabolites, 3-HDMB (major) and 4-HDMB (minor) were detected and 272 determined in serum samples collected following a single oral administration (in dose of 0.8 mg/kg) to two mares. The 2-HDMB was monitored as probable metabolite of BH. However, 273 274 it was not detected in any of the real samples. Exemplary LC-MS/MS chromatograms obtained 275 for the calibration solution at c=1 ng/mL for all target analytes fortified with ISTD at c=1 ng/mL276 and a real serum sample collected from horse H1 in 1 h post-administration fortified with ISTD

277 at c=1 ng/mL are presented in Fig. 3. The parent drug was found at higher concentration levels 278 than its metabolites with the maximum concentration (C_{max}) within 18.2 – 23.7 ng/mL found in 279 1 h post-administration (t_{max}). The C_{max} values obtained for 3-HDMB (10.26 – 12.72 ng/mL) 280 and 4-HDMB (0.279 – 2.4 ng/mL) were found in 5 – 15.5 h after BH administration. More 281 detailed data on maximum concentrations obtained for BH and its metabolites are presented in 282 Table 4. Although the parent drug was found at higher concentrations than 3-HDMB and 283 4-HDMB, both BH metabolites lasted for a longer period of time in equine serum. The parent 284 drug was detectable at up to 29.25 - 35 h post-administration, while 3-HDMB at up to 59.5 h 285 in serum samples collected from both horses, and 4-HDMB at up to 35 – 53 h. BH, 3-HDMB, 286 and 4-HDMB serum concentrations over time curves are shown in Fig. 2. Serum concentrations 287 of BH and its metabolites (4-HDMB and 3-HDMB) swing up and down wildly. Each of the 288 examined compound (BH, 4-HDMB and 3-HDMB) serum concentration has a peak around 289 15-20 h. These phenomena are closely related to the process of drug absorption, which is linked 290 to the route of administration of the drug (BH was orally administered with feed to horses H1 291 and H2 for 30 and 40 min, respectively), race, age, sex, diet, physical effort as well as inter-292 and intra-individual variability of the drug elimination. In this case the explanation of 293 metabolites and parent compound concentration increase may be mainly connected to the drug 294 administration process, dissolution profile of the drug itself and the dissolution from the horses' 295 digestion system.

297

298

299

300

301

296 Conclusions

The presented LC-MS/MS-based method allows for a quick, simultaneous determination of BH and its metabolites, including 3-HDMB (major) and 4-HDMB (minor), as well as 2-HDMB. The fast and simple sample preparation procedure was based on only two operations: protein precipitation through the use of acetonitrile and centrifugation of samples. The assay was fully validated achieving low limits of detection (0.0057 – 0.0078 ng/mL), high

302 recoveries (94.8 - 105.65%) and good repeatability (CV<9.6%) for all analytes. Thus, the 303 proposed method seems to be suitable for routine doping control analysis.

304 The assay was successfully applied to the analysis of real samples collected after a single 305 oral administration of BH to two healthy mares. Time curses of BH and its metabolites 306 (3-HDMB and 4-HDMB) concentrations in equine serum were determined for the first time. 307 The 2-HDMB, which was considered as a probable BH metabolite, was not found in the real 308 samples. The parent drug was found at higher concentration levels than 3-HDMB (major 309 metabolite) and 4-HDMB (minor metabolite), however, both BH metabolites can be considered 310 as appropriate BH abuse markers because they lasted for a longer period of time in equine 311 serum. Nevertheless, the presented data were obtained from the pilot study involving only two 312 horses in the experiment. Therefore, more extensive study may be needed in the future.

Acknowledgements This work was supported by the Polish National Science Center [grant
number 2016/21/N/ST4/02342].

315 **Conflict of interest statement** The authors declare that they have no conflict of interest.

316 5. References

317 [1] A.G. Fragkaki, N. Kioukia-Fougia, P. Kiousi, M. Kioussi, M. Tsivou, Challenges in
318 detecting substances for equine anti-doping, Drug Test Anal. 9 (2017) 1291-1303.

319 [2] https://www.ifhaonline.org/resources/2018Agreement.pdf (Accessed 14 March 2019).

320 [3] https://inside.fei.org/sites/default/files/2019%20Prohibited%20Substances%20List_0.pdf
321 (Accessed 29 March 2019).

[4] E. Schraven, F.W. Koss, J. Keck, G. Beisenherz, Excretion, isolation and identification of
the metabolites of Bisolvon®, Eur. J. Pharmacol. 1 (1967) 445-451.

- 324 [5] Z. Kopitar, R. Jauch, R. Hankwitz, H. Pelzer, Species difference in metabolism and
 325 excretion of bromhexine in mice, rats, rabbits, dogs and man, J. Pharmacol. 21 (1973) 6-10.
- [6] L.A. Meijer, J.C.M. Verstegen, S. Bull, J. Fink-Gremmels, Metabolism of bromhexine in
 pig hepatocyte cultures, J. Vet. Pharmacol. Ther. 27 (2004) 219-225.
- [7] J. Liu, X. Chen, Y. Hu, G. Cheng, D. Zhong, Quantification of the major metabolites of
 bromhexine in human plasma using RRLC-MS/MS and its application to pharmacokinetics, J
 Pharm Biomed Anal. 51 (2010) 1134-1141.
- [8] P. de Backer, L.M. Vandecasteele-Thienpont, J.A. Jonckheere, F.M. Belpaire, M.
 Debackere, A.P. de Leenheer, Bioavailability of bromhexine in the horse, Zentralbl
 Veterinarmed A. 27 (1980) 740-745.
- [9] C.E. Uboh, J.A. Rudy, L.R. Soma, M. Fennell, L. May, R. Sams, F.A. Railing, J.
 Shellenberger, M. Kahler, Characterization of bromhexine and ambroxol in equine urine: effect
 of furosemide on identification and confirmation, J Pharm Biomed Anal. 9 (1991) 33-39.
- [10] T. Pereze-Ruiz, C. Martineze-Lozano, A. Sanz, E. Bravo, Determination of bromhexine
 and ambroxol in pharmaceutical dosage forms, urine and blood serum, J. Chromatogr. B 692
 (1997) 199-205.
- [11] M. Javanbakht, M. H. Namjumanesh, B. Akbari-adergani, Molecularly imprinted solidphase extraction for the selective determination of bromhexine in human serum and urine with
 high performance liquid chromatography, Talanta 80 (2009) 133-138.
- [12] M.H. Botterblom, T.J. Janssen, P.J. Guelen, T.B. Vree, Rapid and sensitive determination
 of ambroxol in human plasma and urine by high-performance liquid chromatography, J
 Chromatogr. 421 (1987) 211-215.

- [13] M. Nobilis, J. Pastera, D. Svoboda, J. Kvêtina, K. Macek, High-performance liquid
 chromatographic determination of ambroxol in human plasma, J Chromatogr. 23 (1992)
 251-255.
- [14] T. Perez-Ruiz, C. Martinez-Lozano, A. Sanz, S. Mondejar, Flow-injection extractionspectrophotometric determination of bromhexine with orange IV, J. Pharm Biomed Anal. 13
 (1995) 1101-1106.
- [15] A.C.B. Dias, J.L.M. Santos, J.L.F.C. Lima, E.A.G. Zagatto, Multi-pumping flow system
 for spectrophotometric determination of bromhexine, Anal. Chim. Acta 499 (2003) 107-113.
- 354 [16] V. Tantishaiyakul, C. Poeaknapo, P. Sribun, K. Sirisuppanon, Simultaneous determination
- 355 of dextromethorphan HBr and bromhexine HCl in tablets by first-derivative spectrophotometry,
- 356 J. Pharm Biomed Anal. 17 (1998) 237-243.
- [17] E. Sumarlik, G. Indrayanto, TLC desitometric determination of bromhexine hydrochloride
 in pharmaceuticals, and its validation, J. Liq. Chrom. & Relat. Technol. 27 (2004) 2047-2056.
- [18] D. C. Oliva, K. T. Vélez, A. L. R. Vázquez, Simultaneous Determination of Bromhexine
 and Amoxicillin in Pharmaceutical Formulations by Capillary Electrophoresis, J. Mex. Chem.
 Soc. 55 (2011) 79-83.
- [19] P. N. S Pai, G. K. Rao, M. S. Murthy, A. Agarwal, S. Puranik, Simultaneous Determination
 of Salbutamol Sulphate and Bromhexine Hydrochloride in Tablets by Reverse Phase Liquid
 Chromatography, Indian J Pharm Sci. 71 (2009) 53–55.
- [20] A. Porel, Sanjukta Haty, A. Kundu, Stability-indicating HPLC Method for Simultaneous
 Determination of Terbutaline Sulphate, Bromhexine Hydrochloride and Guaifenesin, Indian J
 Pharm Sci. 73 (2011) 46–56.

368	[21] P. M. Njaria, K. O. Abuga, F. N. Kamau, H. K. Chepkwony, A Versatile HPLC Method
369	for the Simultaneous Determination of Bromhexine, Guaifenesin, Ambroxol,
370	Salbutamol/Terbutaline, Pseudoephedrine, Triprolidine, and Chlorpheniramine Maleate in
371	Cough–Cold Syrups, Chromatographia 79 (2016) 1507-1514.

- 372 [22] W. Zhang, F. Feng, Y. Wang, Bioequivalence study of bromhexine by liquid
 373 chromatography–electrospray ionization-mass spectrometry after oral administration of
 374 bromhexine hydrochloride tablets, J. Pharm Biomed Anal. 48 (2008) 1206-1210.
- 375 [23] https://www.fda.gov/downloads/drugs/guidances/ucm073384.pdf (Accessed 12 April
 376 2019).
- 377 [24] https://www.fda.gov/media/70858/download (Accessed 12 April 2019).
- 378 [25] https://pacificbiolabs.com/wp-content/uploads/2017/12/Q2_R1__Guideline-4.pdf
 379 (Accessed 12 April 2019).
- 380 [26] https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-
- 381 method-validation_en.pdf (Accessed 20 February 2019).



Fig. 1 LC-MS/MS chromatograms obtained for: (A) calibration solution at c=1 ng/mL for all
target analytes fortified with ISTD at c=1 ng/mL; (B) real serum sample collected from horse
H1 in 1 h post-administration fortified with ISTD at c=1 ng/mL.

383



Fig. 2 Time curves of BH and its metabolites concentrations in equine serum: (A1) BH serum concentrations over time curve for horse H1, (A2) BH serum concentrations over time curve for horse H2, (B1) 3-HDMB serum concentrations over time curve for horse H1, (B2) 3-HDMB serum concentrations over time curve for horse H2, (C1) 4-HDMB serum concentrations over time curve for horse H1, (C2) 4-HDMB serum concentrations over time curve for horse H2.

394

387

- 395 List of tables
- **Table 1.** Optimized MS/MS conditions for positive mode MRM analysis for target analytes.
- 397 Table 2. Data obtained from the equations of calibration curves, including information on
 398 linearity, matrix effects, limit of detection and quantification.
- **Table 3.** Intra- and inter-day accuracy and precision, recovery ±SD, stability.
- 400 **Table 4.** Maximum concentrations of BH and its metabolites in equine serum obtained after a
- 401 single oral administration of BH to two horses.

402 Supplementary material

- 403 Supplementary Table 1. Recovery rates obtained for all the analytes when ACN and MeOH404 was used as the solvent for the deproteinization.
- 405 Supplementary Figure 1. The chromatograms obtained in preliminary studies using: (A)
- 406 Ascentis Express® C18 column (15 cm \times 2.1 mm, 2.7 μ m) with guard column (0.5 cm \times 2.1
- 407 mm, 2.7 μ m), (B) Kinetex core-shell C18 column (15 cm \times 2.1 mm, 2.6 μ m) with guard column
- 408 $(0.5 \text{ cm x } 2.1 \text{ mm}, 2.6 \mu \text{m})$ from Phenomenex (Torrance, USA).

Compound	Molecular formula	Chemical structure	Precursor ion quantifier ion qualifier ion 	Collision energy [V]	Dwell time [msec]	RT [min]
ВН	$C_{14}H_{20}Br_2N_2$	Br NH ₂	M+H [m/z] 376.9 ▶ 114.25 ▶ 263.9	 ▶ -17 ▶ -29 		4.23
2-HDMB	$C_{13}H_{18}Br_2N_2O$	OH NH ₂ Br	378.9 ▶ 116.2 ▶ 263.9	 ▶ -20 ▶ -17 	07	3.26
3-HDMB	$C_{13}H_{18}Br_2N_2O$	OH NH ₂ Br	378.9 ▶ 116.2 ▶ 263.9	 ▶ -20 ▶ -17 	97	2.47
4-HDMB	$C_{13}H_{18}Br_2N_2O$	HO NH ₂ Br	378.9 ▶ 263.9 ▶ 116.2	 ▶ -20 ▶ -17 		2.12
Diphenhydramine (ISTD)	C ₁₇ H ₂₁ NO		256.1 ➤ 167.2 ➤ 152.1	 ▶ -14 ▶ -37 		3.69

Table 1 Optimized MS/MS conditions for positive mode MRM analysis for target analytes.

Table 2. Data obtained from the equations of calibration curves, including information on linearity, matrix effects, limit of detection and quantification.

Compound	Calibration range	Calibration curve	Sa	Sb	Linearity	LOD/LOQ	ME (%)
	(ng/mL)	equation			(\mathbf{R}^2)	(ng/mL)	
BH	0.025 – 1	y=0.128x + 0.0298	0.0012	0.0002	0.9971	0.0052/0.016	-21.6
	1 - 500	y=0.0043x + 0.0001	0.000049	0.0013	0.9995		-34.6
2-HDMB	0.025 – 1	y=0.0927x + 0.0027	0.00089	0.00015	0.9951	0.0053/0.016	-33.6
	1 - 500	y=0.0023x + 0.0008	0.000011	0.00030	0.9997		-10.4
3-HDMB	0.025 - 1	y=0.0509x - 0.0001	0.00053	0.000087	0.9983	0.0056/0.017	-41.4
	1 - 500	y=0.0016x + 0.0033	0.000098	0.00026	0.9994		-1.2
4-HDMB	0.025 – 1	y=0.1313x - 0.0009	0.0010	0.00017	0.9978	0.0043/0.013	-32.9
	1 - 500	y=0.0037x +0.012	0.000027	0.00071	0.9993		-3.4

 S_a : standard deviations of slope; S_b : standard deviations of constant terms; R^2 : coefficient of determination; LOD: limit of detection; LOQ: limit of quantification.

Compound	Calibration	Concentration	Intra-day	Inter-day	RE (%) ± SD	Stability: accuracy (precision) (%)		
	range	of quality	accuracy	accuracy	(<i>n</i> =6)	RT (<i>n</i> =6)	4°C (<i>n</i> =6)	Three
	(ng/mL)	control sample	(precision) (%)	(precision)				freeze/thaw
		(ng/mL)	(<i>n</i> =6)	(%) (<i>n</i> =18)				cycles (<i>n</i> =6)
BH	0.025 – 1	C ₁ =0.05	93.5 - 106.3	99.7 (7.4)	94.8 ± 7.5	993(48)	963(31)	102 7 (9 9)
			(2.4 – 9.4)		J 1.0 ± 7.5	<i>уу.</i> (1.0)	70.5 (3.1)	102.7 (9.9)
		C ₂ =0.25	98.1 - 108.8	102.4 (6.5)	104.21 ± 0.87	98.1 (0.41)	100.8 (1.9)	106.6 (0.86)
			(0.20 – 7.3)		104.21 ± 0.07	J0.1 (0.+1)	100.0 (1.9)	100.0 (0.00)
		C ₃ =1	104.0 - 104.7	105.8 (4.4)	105.65 ± 0.14	105.6 (0.14)	103 3 (2 3)	108 1 (1 7)
			(1.6 – 8.1)		105.05 ± 0.14	105.0 (0.14)	105.5 (2.5)	100.1 (1.7)
	1 - 500	C ₁ =5	93.3 - 102.6	98.0 (5.9)	98.3 ± 1.5	103.9 (6.0)	108.9 (0.43)	96.2 (6.4)
			(2.8 – 5.8)		76.5 ± 1.5	105.7 (0.0)	100.7 (0.43)	<i>J</i> 0.2 (0.4)
		C ₂ =50	91.6 - 94.8	93.4 (2.4)	97.6 + 1.1	104.6 (7.6)	103.6 (0.66)	95 4 (5 4)
			(1.5 – 2.8)		J7.0 ± 1.1	104.0 (7.0)	103.0 (0.00)))), (), (), (), (), (), (), (), (), (),
		C ₃ =200	98.7 - 102.1	100.6 (2.1)	94.8 ± 1.0	100.2(1.7)	101 7 (0.80)	100 3 (0 92)
			(0.12 – 3.0)		J4.0 ± 1.0	100.2 (1.7)	101.7 (0.00)	100.5 (0.92)
2-HDMB	0.025 – 1	C1=0.05	96.0 - 100.9	97.9 (3.3)	102.9 ± 7.2	1077(42)	91.6(5.6)	971(18)
			(1.4 – 3.8)		102.7 - 1.2	107.7 (4.2)	71.0 (5.0)	<i>J1</i> .1 (1.0)
		C ₂ =0.25	98.2 - 109.1	102.2 (5.9)	100.2 + 2.8	29 101 1 (20) 05 6 (0.26)	95.6 (0.36)	98.0 (1.5)
			(0.96 – 5.0)		100.3 ± 2.0	101.1 (2.9)	<i>75</i> .0 (0.50)	70.0 (1.3)

Table 3. Intra- and inter-day accuracy and precision, recovery \pm SD, stability.

		C ₃ =1	104.8 - 105.4 (2.3 - 3.9)	105.2 (2.6)	97.9 ± 9.3	107.6 (2.0)	107.4 (3.9)	108.4 (1.1)
	1 - 500	C ₁ =5	92.7 – 96.7 (1.4 – 3.4)	94.8 (2.8)	98.3 ± 1.1	100.3 (0.72)	109.7 (0.78)	107.2 (5.9)
		C ₂ =50	98.4 - 101.9 (1.4 - 3.1)	100.4 (2.3)	100.1 ± 4.2	109.8 (3.9)	106.1 (7.7)	100.2 (5.5)
		C ₃ =200	99.1 - 101.8 (0.21 - 1.4)	100.8 (1.5)	101.0 ± 3.8	99.3 (2.2)	97.2 (1.9)	99.7 (7.2)
3-HDMB	0.025 – 1	C ₁ =0.05	97.5 – 100.5 (1.4 – 9.6)	98.8 (4.8)	99.3 ± 4.2	103.9 (1.8)	101.0 (2.8)	102.1 (3.6)
		C ₂ =0.25	94.4 - 102.1 (5.6 - 8.2)	98.9 (6.4)	100.6 ± 5.2	106.6 (4.6)	103.2 (3.5)	99.2 (5.5)
		C3=1	95.4 - 100.8 (1.4 - 4.1)	97.9 (3.3)	101.0 ± 3.8	94.8 (1.6)	107.8 (7.2)	108.0 (1.6)
	1 – 500	C1=5	99.0 - 101.5 (0.27 - 2.9)	100.1 (1.9)	97.5 ± 2.5	108.2 (1.6)	108.9 (7.1)	107.8 (1.4)
		C ₂ =50	102.3 – 105.7 (1.6 – 2.2)	104.3 (2.1)	96.5 ± 2.2	104.9 (1.4)	104.9 (3.0)	105.8 (0.70)
		C ₃ =200	102.6 - 104.5 (0.44 - 1.2)	103.8 (1.2)	101.3 ± 4.8	107.2 (1.4)	103.2 (1.4)	102.5 (0.46)

4-HDMB	0.025 – 1	C ₁ =0.05	92.6 - 94.9 (0.41 - 0.60)	93.8 (1.2)	94.5 ± 3.5	98.0 (3.7)	91.8 (1.2)	102.6 (0.97)
		C ₂ =0.25	97.2 – 103.3 (1.1 – 3.4)	99.8 (3.6)	100.3 ± 5.5	103.6 (3.2)	101.1 (2.2)	96.7 (2.2)
		C ₃ =1	107.7 – 108.6 (1.8 – 5.2)	108.2 (2.8)	101.1 ± 2.9	109.5 (1.5)	105.1 (2.5)	107.7 (0.19)
	1 – 500	C ₁ =5	99.0 - 107.3 (0.14 - 3.2)	104.2 (4.7)	103.9 ± 5.4	104.2 (7.7)	101.0 (2.6)	109.7 (2.2)
		C ₂ =50	101.8 – 105.3 (1.7 – 2.1)	103.5 (3.3)	102.2 ± 2.2	108.6 (6.2)	99.1 (2.6)	108.1 (1.3)
		C ₃ =200	105.5 - 106.9 (0.18 - 1.5)	106.4 (1.0)	100.6 ± 2.2	106.3 (1.6)	106.0 (2.1)	105.8 (0.55)

n: number of measurements; RE: recovery; CV: coefficient of variation; RT: room temperature.

Horse name		H1	H2	
BH dose (mg/kg)		0.8		
BH	C_{max} (ng/mL ±SD; $n=3$)	23.7 ± 1.8	18.2 ± 1.1	
	t _{max} (h)	1	1	
3-HDMB	C_{max} (ng/mL ±SD; $n=3$)	12.72 ± 0.82	10.26 ± 0.54	
	t _{max} (h)	15.5	5	
4-HDMB	C_{max} (ng/mL ±SD; $n=3$)	2.40 ± 0.12	0.279 ± 0.016	
	t _{max} (h)	15.5	5	

Table 4. Maximum concentrations of BH and its metabolites in equine serum obtained after a single oral administration of BH to two horses.

Supplementary Figure 1. The chromatograms obtained in preliminary studies using: (A) 406 Ascentis Express® C18 column (15 cm \times 2.1 mm, 2.7 µm) with guard column (0.5 cm \times 2.1mm, 2.7 µm), (B) Kinetex core-shell C18 column (15 cm \times 2.1 mm, 2.6 µm) with guard column (0.5 cm \times 2.1 mm, 2.6 µm) from Phenomenex (Torrance, USA).



MOST WIEDZY Downloaded from mostwiedzy.pl

Compound	Concentration of QC (ng/mL)	RE (%) ± SD (<i>n</i> =3)		
		МеОН	ACN	
BH	C ₁ =0.25	99.1 ± 4.6	73.7 ± 5.7	
	C ₂ =50	97.7 ± 4.1	73.0 ± 2.8	
2-HDMB	C ₁ =0.25	97.8 ± 1.5	74.2 ± 1.6	
	C ₂ =50	97.7 ± 1.7	73.3 ± 2.1	
3-HDMB	C ₁ =0.25	97.6 ± 5.0	77.9 ± 5.8	
	C ₂ =50	98.2 ± 3.9	77.9 ± 5.0	
4-HDMB	C ₁ =0.25	109.3 ± 2.3	70.0 ± 2.2	
	C ₂ =50	108.4 ± 2.8	73.9 ± 1.6	

Supplementary Table 1. Recovery obtained for all the analytes when ACN and MeOH was used as the solvent for the deproteinization.

n: number of measurements; RE: recovery.